[
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer",
        "summary": "Listen to a soundcast of the June 13, 2024, and June 21, 2024, Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors&nbsp;and Krazati (adagrasib)&nbsp;for&nbsp;KRAS G12C-mutated colorectal cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-augtyro-repotrectinib-ntrk-gene-fusion-positive-solid-tumors",
        "published": "Fri, 16 Aug 2024 14:22:19 EDT",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer",
        "summary": "Listen to a soundcast of the December 9 and 12, 2022, FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer\u201d",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-tecentriq-atezolizumab-unresectable-or-metastatic-alveolar",
        "published": "Mon, 23 Jan 2023 11:54:30 EST",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Vijoice (alpelisib) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy",
        "summary": "Listen to a soundcast of the 4/5/2022 FDA approval of Vijoice (alpelisib)  for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-vijoice-alpelisib-adult-and-pediatric-patients-two-years-age",
        "published": "Wed, 27 Apr 2022 09:38:28 EDT",
        "keywords": [
            "PIK3CA"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Verzenio (abemaciclib) for adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer, & Keytruda (pembrolizumab) for persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS\u202f\u22651)",
        "summary": "FDA approvals of Verzenio (abemaciclib) for adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer, &amp; Keytruda (pembrolizumab) for persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS\u202f\u2265",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-verzenio-abemaciclib-adjuvant-treatment-adult-patients-hormone",
        "published": "Mon, 25 Oct 2021 12:18:46 EDT",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Lumakras (sotorasib) for patients with KRAS G12C  mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq (infigratinib) for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement",
        "summary": "Listen to a soundcast of the May 28, 2021, approvals of Lumakras for patients with KRAS G12C\u2011mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-lumakras-sotorasib-patients-kras-g12c-mutated-locally-advanced",
        "published": "Thu, 17 Jun 2021 08:57:39 EDT",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Trodelvy (sacituzumab govitecan) for locally advanced/metastatic urothelial cancer who received platinum-containing chemotherapy & either PD-1/PD-L1 inhibitor and Opdivo (nivolumab) in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma",
        "summary": "Trodelvy (sacituzumab govitecan) for locally advanced/metastatic urothelial cancer who received platinum-containing chemotherapy &amp; either PD-1/PD-L1 inhibitor. Opdivo (nivolumab) in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-trodelvy-sacituzumab-govitecan-locally-advancedmetastatic",
        "published": "Fri, 23 Apr 2021 13:35:39 EDT",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression with no eGFR, anaplastic lymphoma kinase or receptor tyrosine kinase aberrations",
        "summary": "Listen to a soundcast of the February 22nd 2021 FDA approval of Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-libtayo-cemiplimab-rwlc-first-line-treatment-patients-advanced-nsclc-locally",
        "published": "Fri, 12 Mar 2021 06:01:35 EST",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.genomeweb.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.genomeweb.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.360dx.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Natera MRD Study Results Demonstrate Potential to Ressurect Failed Adjuvant Drugs",
        "summary": "<p><span><span><span>The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/natera-mrd-study-results-demonstrate-potential-ressurect-failed-adjuvant-drugs",
        "published": "Mon, 27 Jan 2025 15:47:45 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.360dx.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Angle Looks to Dual CTC, ctDNA Analysis, Illumina Tie-up to Expand Cancer Dx, CDx Business",
        "summary": "<p>Assaying both CTCs and ctDNA simultaneously offers a path to more accurate and early cancer detection and drug response monitoring.</p>",
        "link": "https://www.genomeweb.com/cancer/angle-looks-dual-ctc-ctdna-analysis-illumina-tie-expand-cancer-dx-cdx-business",
        "published": "Thu, 06 Feb 2025 14:41:30 EST",
        "keywords": [
            "CDx",
            "ctDNA"
        ]
    },
    {
        "title": "Aiosyn Growing Team, Ramping up Sales of Breast Cancer Mitosis Detection Tool",
        "summary": "<p><span><span><span>The digital pathology software developer is raising funding that would help it to increase its head count and support its Aiosyn Mitosis Breast application.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/aiosyn-growing-team-ramping-sales-breast-cancer-mitosis-detection-tool",
        "published": "Fri, 07 Feb 2025 08:45:22 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Roche, Abbott, Inflammatix, Paige, Others Gain 510(k) Clearances in January",
        "summary": "<p><span><span><span>The US Food and Drug Administration in January granted 510(k) marketing clearances for a 30-minute sepsis test, digital pathology software, and various infectious disease tests</span></span></span></p>",
        "link": "https://www.360dx.com/regulatory-news-fda-approvals/roche-abbott-inflammatix-paige-others-gain-510k-clearances-january",
        "published": "Tue, 11 Feb 2025 17:02:24 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Perspective: Neurofilament Light as a Biomarker in Mouse Models to Advance Research in Neurological Disorders",
        "summary": "<p>The ability to measure NfL levels with high sensitivity in mouse models is transforming how researchers study neurological disorders, allowing for earlier and more precise insights into disease mechanisms and therapeutic responses.</p>",
        "link": "https://www.genomeweb.com/neurological-psychological-disorders/perspective-neurofilament-light-biomarker-mouse-models-advance",
        "published": "Fri, 14 Feb 2025 00:01:21 EST",
        "keywords": [
            "NFL"
        ]
    },
    {
        "title": "Foundation Medicine, Sumitomo Pharma to Develop CDx for Acute Leukemia Treatment",
        "summary": "<p><span><span><span>The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/foundation-medicine-sumitomo-pharma-develop-cdx-acute-leukemia-treatment",
        "published": "Tue, 18 Feb 2025 10:03:43 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Foundation Medicine, Sumitomo Pharma to Develop CDx for Acute Leukemia Treatment",
        "summary": "<p><span><span><span>The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/foundation-medicine-sumitomo-pharma-develop-cdx-acute-leukemia-treatment",
        "published": "Tue, 18 Feb 2025 10:03:43 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Veracyte Eyes Dropping IVD/Pharma Subsidiary in Europe As Growth Concentrates Among Clinical LDTs",
        "summary": "<p><span><span><span><span><span><span>Company officials lauded its core tests and shared news about launches planned for the upcoming year, including its minimal residual disease assay.</span></span></span></span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/veracyte-eyes-dropping-ivdpharma-subsidiary-europe-growth-concentrates-among-clinical-ldts",
        "published": "Tue, 25 Feb 2025 10:43:26 EST",
        "keywords": [
            "Veracyte"
        ]
    },
    {
        "title": "Veracyte Eyes Dropping IVD/Pharma Subsidiary in Europe As Growth Concentrates Among Clinical LDTs",
        "summary": "<p><span><span><span><span><span><span>Company officials lauded its core tests and shared news about launches planned for the upcoming year, including its minimal residual disease assay.</span></span></span></span></span></span></p>",
        "link": "https://www.360dx.com/cancer/veracyte-eyes-dropping-ivdpharma-subsidiary-europe-growth-concentrates-among-clinical-ldts",
        "published": "Tue, 25 Feb 2025 10:43:26 EST",
        "keywords": [
            "Veracyte"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/biotech/bridgebios-kras-focused-cancer-spinout-backs-spac-path-nasdaq\" hreflang=\"en\">BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq</a>",
        "summary": "For a while, special purpose acquisition companies were biotech\u2019s hot ticket to the public markets. While interest in this path has died down in recent years, BridgeBio\u2019s former cancer unit thinks it could work for them.",
        "link": "https://www.fiercebiotech.com/biotech/bridgebios-kras-focused-cancer-spinout-backs-spac-path-nasdaq",
        "published": "Feb 28, 2025 9:02am",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "Epredia Gains FDA 510(k) for Digital Pathology Imaging System",
        "summary": "<p><span><span><span>The firm's E1000 Dx Digital Pathology Solution consists of an automated scanner, whole-slide image viewer, and image management and viewing software.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/epredia-gains-fda-510k-digital-pathology-imaging-system",
        "published": "Tue, 04 Mar 2025 09:48:32 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Foresight Diagnostics Launches Trial of MRD-Guided Treatment in Hodgkin Lymphoma",
        "summary": "<p><span><span>Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy. \u00a0</span></span></p>",
        "link": "https://www.genomeweb.com/cancer/foresight-diagnostics-launches-trial-mrd-guided-treatment-hodgkin-lymphoma",
        "published": "Wed, 05 Mar 2025 11:52:46 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Tethis, Sheba Medical Center Trying to Predict Rectal Cancer Relapse Earlier With CTCs, ctDNA",
        "summary": "<p><span><span>Sheba researchers will use Tethis' technology to prepare patients' blood samples for circulating tumor cells and circulating tumor DNA analysis.</span></span></p>",
        "link": "https://www.genomeweb.com/cancer/tethis-sheba-medical-center-trying-predict-rectal-cancer-relapse-earlier-ctcs-ctdna",
        "published": "Mon, 10 Mar 2025 14:04:06 EDT",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Agilent Technologies Gains Expanded IVDR Certification for PD-L1 CDx",
        "summary": "<p><span><span><span>The test has been certified for use in the EU to help guide the treatment of early-stage non-small cell lung cancer and previously untreated advanced melanoma.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/agilent-technologies-gains-expanded-ivdr-certification-pd-l1-cdx",
        "published": "Mon, 10 Mar 2025 10:06:38 EDT",
        "keywords": [
            "CDx",
            "PD-L1"
        ]
    },
    {
        "title": "Roche, Abbott, Hologic, Cepheid, Others Gain 510(k) Clearances in February",
        "summary": "<p><span><span><span>The US Food and Drug Administration granted last month clearances for a preeclampsia risk test, respiratory disease tests, and a digital pathology system, among others.</span></span></span></p>",
        "link": "https://www.360dx.com/regulatory-news-fda-approvals/roche-abbott-hologic-cepheid-others-gain-510k-clearances-february",
        "published": "Wed, 12 Mar 2025 15:24:00 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Pharma, Dx Leaders Urge MRD Community to Focus on Clinical Utility as Use in Trials Grows",
        "summary": "<p><span><span><span>A discussion at last week's Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/pharma-dx-leaders-urge-mrd-community-focus-clinical-utility-use-trials-grows",
        "published": "Mon, 17 Mar 2025 15:22:17 EDT",
        "keywords": [
            "MRD"
        ]
    },
    {
        "title": "Pharma, Dx Leaders Urge MRD Community to Focus on Clinical Utility as Use in Trials Grows",
        "summary": "<p><span><span><span>A discussion at last week's Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/pharma-dx-leaders-urge-mrd-community-focus-clinical-utility-use-trials-grows",
        "published": "Mon, 17 Mar 2025 15:22:17 EDT",
        "keywords": [
            "MRD"
        ]
    },
    {
        "title": "Prosica Nabs $50M in Funding to Support Commercialization of Digital Pathology Software",
        "summary": "<p><span><span><span>The firm said that the money will support work with OEM partners and the expanded development and integration of artificial intelligence-based tools. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/prosica-nabs-50m-funding-support-commercialization-digital-pathology-software",
        "published": "Wed, 19 Mar 2025 14:27:50 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Epredia Bolsters Cancer Testing Menu With High-Throughput Digital Pathology System",
        "summary": "<p><span><span><span>The precision cancer business of PHC Holdings anticipates an increase in cancer cases and is expanding its digital pathology and immunohistochemistry instrument lineup.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/epredia-bolsters-cancer-testing-menu-high-throughput-digital-pathology-system",
        "published": "Wed, 19 Mar 2025 09:40:30 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Gestalt, Primaa Partner on AI-Based Testing for Skin Cancer",
        "summary": "<p><span><span><span>The firms said that they will integrate Primaa's skin cancer testing algorithms with Gestalt's PathFlow digital pathology software platform.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/gestalt-primaa-partner-ai-based-testing-skin-cancer",
        "published": "Wed, 19 Mar 2025 14:38:15 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Craig-Hallum Initiates Coverage of Veracyte With Buy Rating, $45 Price Target",
        "summary": "<p><span><span><span>The investment bank views the company as a promising target with a strong track record and prospects for expansion into new, under-penetrated markets.</span></span></span></p>",
        "link": "https://www.genomeweb.com/business-news/craig-hallum-initiates-coverage-veracyte-buy-rating-45-price-target",
        "published": "Thu, 20 Mar 2025 10:44:48 EDT",
        "keywords": [
            "Veracyte"
        ]
    },
    {
        "title": "Executive Q&A: NCCN Recommends ctDNA MRD Testing for Diffuse Large B-Cell Lymphoma",
        "summary": "<p>In this GenomeWeb Executive Q&amp;A, Foresight Diagnostics\u2019 chief operating and compliance officer Sandra Close and chief business officer John Truesdell discuss the new guidelines, how they may change the treatment journey for diffuse large B-cell lymphoma patients, and Foresight's approach to establishing the clinical utility of its tests.</p>",
        "link": "https://www.genomeweb.com/liquid-biopsy/executive-qa-nccn-recommends-ctdna-mrd-testing-diffuse-large-b-cell-lymphoma",
        "published": "Thu, 20 Mar 2025 09:45:46 EDT",
        "keywords": [
            "ctDNA",
            "MRD"
        ]
    },
    {
        "title": "Craig-Hallum Initiates Coverage of Veracyte With Buy Rating, $45 Price Target",
        "summary": "<p><span><span><span>The investment bank views the company as a promising target with a strong track record and prospects for expansion into new, under-penetrated markets.</span></span></span></p>",
        "link": "https://www.360dx.com/business-news/craig-hallum-initiates-coverage-veracyte-buy-rating-45-price-target",
        "published": "Thu, 20 Mar 2025 10:44:48 EDT",
        "keywords": [
            "Veracyte"
        ]
    },
    {
        "title": "Proscia Nabs $50M in Funding to Support Commercialization of Digital Pathology Software",
        "summary": "<p><span><span><span>The firm said that the money will support work with OEM partners and the expanded development and integration of artificial intelligence-based tools. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/proscia-nabs-50m-funding-support-commercialization-digital-pathology-software",
        "published": "Wed, 19 Mar 2025 14:27:50 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Siemens Healthineers Gains FDA 510(k) Clearance for Blood Clot Drug CDx",
        "summary": "<p><span><span><span>The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.</span></span></span></p>",
        "link": "https://www.360dx.com/hematologycoagulation/siemens-healthineers-gains-fda-510k-clearance-blood-clot-drug-cdx",
        "published": "Mon, 31 Mar 2025 09:51:33 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "New Data Promising for Veracyte on Path to Launch Whole-Genome Sequencing MRD Test",
        "summary": "<p><span><span><span>The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/new-data-promising-veracyte-path-launch-whole-genome-sequencing-mrd-test",
        "published": "Mon, 31 Mar 2025 15:34:18 EDT",
        "keywords": [
            "Veracyte",
            "MRD"
        ]
    },
    {
        "title": "New Data Promising for Veracyte on Path to Launch Whole-Genome Sequencing MRD Test",
        "summary": "<p><span><span><span>The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/new-data-promising-veracyte-path-launch-whole-genome-sequencing-mrd-test",
        "published": "Mon, 31 Mar 2025 15:34:18 EDT",
        "keywords": [
            "Veracyte",
            "MRD"
        ]
    },
    {
        "title": "Pillar Biosciences Receives CMS Coverage for Pan-Cancer CDx Assay",
        "summary": "<p><span><span><span>The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes. </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/pillar-biosciences-receives-cms-coverage-pan-cancer-cdx-assay",
        "published": "Thu, 03 Apr 2025 10:05:43 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Pillar Biosciences Receives CMS Coverage for Pan-Cancer CDx Assay",
        "summary": "<p><span><span><span>The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/pillar-biosciences-receives-cms-coverage-pan-cancer-cdx-assay",
        "published": "Thu, 03 Apr 2025 10:05:43 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Proscia Using $50M Fundraise to Expand Staff, Bolster AI Tools Menu",
        "summary": "<p><span><span><span>The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.</span></span></span></p>",
        "link": "https://www.360dx.com/diagnostics/proscia-using-50m-fundraise-expand-staff-bolster-ai-tools-menu",
        "published": "Fri, 04 Apr 2025 09:31:15 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Source BioScience Acquires Cambridge Clinical Laboratories",
        "summary": "<p><span><span>UK-based<strong> </strong>Source Bio said the deal will expand its existing molecular diagnostics, digital pathology, and clinical trial support service portfolio.</span></span></p>",
        "link": "https://www.genomeweb.com/molecular-diagnostics/source-bioscience-acquires-cambridge-clinical-laboratories",
        "published": "Thu, 10 Apr 2025 09:47:19 EDT",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Source BioScience Acquires Cambridge Clinical Laboratories",
        "summary": "<p><span><span>UK-based<strong> </strong>Source Bio said the deal will expand its existing molecular diagnostics, digital pathology, and clinical trial support service portfolio.</span></span></p>",
        "link": "https://www.360dx.com/molecular-diagnostics/source-bioscience-acquires-cambridge-clinical-laboratories",
        "published": "Thu, 10 Apr 2025 09:47:19 EDT",
        "keywords": [
            "digital pathology"
        ]
    }
]